Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis

Published:2016-01-19 Issue:4 Volume:23 Page:729-736
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Spelman T.¹²,Mekhael L.³,Burke T.³,Butzkueven H.¹²,Hodgkinson S.⁴,Havrdova E.⁵,Horakova D.⁵,Duquette P.⁶,Izquierdo G.⁷,Grand'Maison F.⁸,Grammond P.⁹,Barnett M.¹⁰,Lechner-Scott J.¹¹,Alroughani R.¹²,Trojano M.¹³,Lugaresi A.¹⁴,Granella F.¹⁵,Pucci E.¹⁶,Vucic S.³,

Affiliation:

1. Department of Neurology; Royal Melbourne Hospital; Parkville Vic. Australia

2. Department of Medicine (RMH); University of Melbourne; Parkville Vic. Australia

3. Westmead Hospital; Sydney NSW Australia

4. Liverpool Hospital; Sydney NSW Australia

5. Charles University; Prague Czech Republic

6. Hôpital Notre Dame; Montreal QC Canada

7. Hospital Universitario Virgen Macarena; Sevilla Spain

8. Neuro Rive-Sud; Hôpital Charles LeMoyne; Quebec QC Canada

9. Center de réadaptation déficience physique Chaudière-Appalache; Levis QC Canada

10. Brain and Mind Research Institute; Sydney NSW Australia

11. John Hunter Hospital; Newcastle NSW Australia

12. Amiri Hospital; Kuwait City Kuwait

13. Department of Basic Medical Sciences; Neuroscience and Sense Organs; University of Bari; Bari Italy

14. MS Center; Department of Neuroscience, Imaging and Clinical Sciences; University ‘G. d'Annunzio’; Chieti Italy

15. Department of Neurosciences; University of Parma; Parma Italy

16. Neurology Unit; ASUR Marche - AV3; Macerata Italy

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.12929/fullpdf

Reference36 articles.

1. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States;Bonafede;Clin Ther,2013

2. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS;Tremlett;Neurology,2003

3. Optimizing adherence to multiple sclerosis therapies;Singer;Int J MS Care,2008

4. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject;Mohr;Ann Behav Med,2001

5. A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events;Brandes;Curr Med Res Opin,2009

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative treatment effectiveness of oral fingolimod and conventional injectable disease‐modifying agents in multiple sclerosis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2021-03-18

2. It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease;Journal of Neurology, Neurosurgery & Psychiatry;2021-02-09

3. Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study;Journal of Neurology, Neurosurgery & Psychiatry;2021-01-12

4. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting;Expert Review of Neurotherapeutics;2020-12-09

5. Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS;Multiple Sclerosis and Related Disorders;2020-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3